Is enoxaparin superior to unfractionated heparin for the actue treatment of NSTEMI?
Metadata[+] Show full item record
Enoxaparin is associated with fewer recurrent ischemic events, does not increase major bleeding events, and is preferred over unfractionated heparin (UFH) for the acute treatment of non-ST-elevation myocardial infarction (NSTEMI) (SOR: A, systematic reviews of RCTs and evidence-based guidelines). Enoxaparin is not recommended for use in NSTEMI patients who will be undergoing coronary artery bypass grafting within 24 hours (SOR: B, evidence-based guideline).
Evidence-based practice 15, no. 11 (2012): 05-06